Citations

Mayo Clinic

Showing 10 of 108522 citations.

Immobile Left Arm in a 2-month-old Infant
Hadley, J, Koti, Ajay , Johnson, Katie L. , Brown, Emily , Hadley, Julia C.

Pediatrics in Review | September 1, 2024 | Volume: 45 | Issue: 9 | Pages: e33-e36

10.1542/pir.2023-006170 | PMID 39217125 Get It

Characterization of flare-ups and impact of garetosmab in adults with fibrodysplasia ossificans progressiva: a post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial
Dahir, Kathryn , McGinniss, Jennifer, Sanchez, Robert J., Mellis, Scott , Rocco, Maja Di , Roux, Christian , Mukaddam, Mona Al , Mohammadi, Kusha , Srinivasan, Dushyanth , Trotter, Dinko González , Pignolo, Robert J. , Dahir, Kathryn M , Sanchez, Robert J , Trotter, Dinko Gonzalez , Keen, Richard , Economides, Aris N. , Orcel, Philippe , Tabarkiewicz, Jacek , Bachiller‐Corral, Javier , Cheung, Angela M. , Gu, Jing , Eekhoff, Elisabeth M. W. , Kaplan, Frederick S.

Journal of Bone and Mineral Research | August 31, 2024 | Volume: 39 | Issue: 10 | Pages: 1486-1492

10.1093/jbmr/zjae140 | PMID 39216107 Get It

Abstract Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare disorder, characterized by progressive heterotopic ossification (HO) and painful soft-tissue inflammatory flare-ups. This was a post hoc analysis from a phase 2 (NCT03188666) trial in which adults with FOP received intravenous anti-activin A antibody garetosmab 10 mg/kg or placebo every 4 wk over 28 wk (Period 1), followed by a 28-wk open-label treatment and extension (Periods 2 and 3). Here we describe flare-ups, their relationship to new HO lesions, and the impact of garetosmab on flare-ups. Volume of new HO lesions was measured by CT. Patient-reported flare-ups were defined by any 2 of the following: new onset of pain, swelling, joint stiffness, decrease in movement, or perceived presence of HO. Flare-ups were experienced by 71% (17/24) of placebo-treated patients, 59% (10/17) of whom developed a new HO lesion irrespective of flare-up location; 24% of flare-ups location-matched new HO lesions. Twenty-nine new HO lesions occurred in the placebo cohort by week 28, of which 12 (41%) occurred in the same location as new or ongoing flare-ups. A higher volume of newly formed heterotopic bone (week 28) occurred in placebo-treated patients who had experienced a prior flare-up vs those without (median [Q1:Q3] of 16.6 [12.0:31.1] vs 3.2 cm3). Garetosmab was previously shown to decrease patient-reported flare-up frequency in Period 1; here, garetosmab reduced the median (Q1:Q3) duration of patient-reported flares (15.0 [6.0:82.0] vs 48.0 [15.0:1.00] d) and the severity of flare-ups vs placebo. Frequency of corticosteroid use was numerically reduced in those treated with garetosmab (40.0%) vs placebo (58.3%). In this analysis, 71% of placebo-treated adults with FOP experienced flare-ups over 28 wk, which were associated with an increased volume of newly formed heterotopic bone. Garetosmab reduced the severity and duration of flare-ups, with effects sustained during the entire trial.
Ibrutinib-induced spinal haematoma in a patient with marginal zone lymphoma
Roberson, Fazela, Yadav, Sumeet K. , Krishnamoorthy, Geetha , Yadav, Sumeet Kumar , Vojjala, Nikhil

BMJ Case Reports | August 31, 2024 | Volume: 17 | Issue: 8 | Pages: e260598

10.1136/bcr-2024-260598 | PMID 39216882 Get It

Bleeding diathesis is an uncommon side effect of ibrutinib use and is seen in less than 5% of the population. We describe a case of an elderly woman with ibrutinib-induced spontaneous major extradural haematoma presenting as acute compressive myelopathy. She is a known case of splenic marginal zone lymphoma with multiple extramedullary relapses and presented to the emergency department with acute-onset low backache, followed by urinary retention. MRI revealed extradural haemorrhage. After possible evaluation, she was diagnosed with ibrutinib-induced extradural haematoma.
Predictors of Mortality by an Artificial Intelligence Enhanced Electrocardiogram Model for Cardiac Amyloidosis
Amadio, Jennifer M. , Grogan, Martha, Lopez‐Jimenez, Francisco, AbouEzzeddine, Omar F. , Lin, Grace , Dasari, Surendra , Borgeson, Daniel D., Friedman, Paul A. , Gertz, Morie A., Murphree, Dennis H. , AbouEzzeddine, Omar, AbouEzzeddine, Omar F , Grogan, Martha , Muchtar, Eli , López-Jiménez, Francisco , Attia, Zachi I. , Kapa, Suraj , Gertz, Morie A. , Dispenzieri, Angela

ESC Heart Failure | August 31, 2024 | Volume: 12 | Issue: 1 | Pages: 677-682

10.1002/ehf2.15061 | PMID 39215684 Get It

Abstract Aims We aim to determine if our previously validated, diagnostic artificial intelligence (AI) electrocardiogram (ECG) model is prognostic for survival among patients with cardiac amyloidosis (CA). Methods A total of 2533 patients with CA (1834 with light chain amyloidosis (AL), 530 with wild-type transthyretin amyloid protein (ATTRwt) and 169 with hereditary transthyretin amyloid (ATTRv)] were included. An amyloid AI ECG (A2E) score was calculated for each patient reflecting the likelihood of CA. CA stage was calculated using the European modification of the Mayo 2004 criteria for AL and Mayo stage for transthyretin amyloid (ATTR). Risk of death was modelled using Cox proportional hazards, and Kaplan–Meier was used to estimate survival. Results Median age of the cohort was 67 [inter-quartile ratio (IQR) 59, 74], and 71.6% were male. The median overall survival for the cohort was 35.6 months [95% confidence interval (CI) 32.3, 39.5]. For AL, ATTRwt and ATTRv, respectively, median survival was 22.9 (95% CI 19.2, 28.2), 47.2 (95% CI 43.4, 52.3) and 61.4 (95% CI 48.7, 75.9) months. On univariate analysis, an increasing A2E score was associated with more than a two-fold risk of all-cause death. On multivariable analysis, the A2E score retained its importance with a risk ratio of 2.0 (95% CI 1.58, 2.55) in the AL group and 2.7 (95% CI 1.81, 4.24) in the ATTR group. Conclusions Among patients with AL and ATTR amyloidosis, the A2E model helps to stratify risk of CA and adds another dimension of prognostication.
Beta-Blocker Use and Outcomes in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fraction
Henderson, Alasdair D , Shen, Li , Campbell, Ross T. , Boer, Rudolf A. de , Lam, Carolyn S.P., Maggioni, Aldo P. , Martínez, Felipe A. , Redfield, Margaret M. , Rouleau, Jean L. , Veldhuisen, Dirk Jan van, Zannad, Faı̈ez , Solomon, Scott, de Boer, Rudolf A , Maggioni, Aldo P , Matsumoto, Shingo , Kondo, Toru , Yang, Mingming , Anand, Inder S. , Desai, Akshay S , Lam, Carolyn S.P. , Packer, Milton , Veldhuisen, Dirk J. van , Vaduganathan, Muthiah , Zile, Michael R. , Jhund, Pardeep S. , McMurray, John J.V.

European Journal of Heart Failure | August 31, 2024 | Volume: 27 | Issue: 1 | Pages: 124-139

10.1002/ejhf.3383 | PMID 39215677 Get It

ABSTRACT Aims In the absence of randomized trial evidence, we performed a large observational analysis of the association between beta-blocker (BB) use and clinical outcomes in patients with heart failure (HF) and mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF). Methods and results We pooled individual patient data from four large HFmrEF/HFpEF trials (I-Preserve, TOPCAT, PARAGON-HF, and DELIVER). The primary outcome was the composite of cardiovascular death or HF hospitalization. Among the 16 951 patients included, the mean left ventricular ejection fraction (LVEF) was 56.8%, and 13 400 (79.1%) had HFpEF (LVEF ≥50%). Overall, 12 812 patients (75.6%) received a BB. The median bisoprolol-equivalent dose of BB was 5.0 (Q1–Q3: 2.5–5.0) mg with BB continuation rates of 93.1% at 2 years (in survivors). The unadjusted hazard ratio (HR) for the primary outcome did not differ between BB users and non-users (HR 0.98, 95% confidence interval [CI] 0.91–1.05), but the adjusted HR was lower in BB users than non-users (0.81, 95% CI 0.74–0.88), and this association was maintained across LVEF (pinteraction = 0.88). In subgroup analyses, the adjusted risk of the primary outcome was similar in BB users and non-users with or without a history of myocardial infarction, hypertension, or a baseline heart rate <70 bpm. By contrast, a better outcome with BB use was seen in patients with atrial fibrillation compared to those without atrial fibrillation (pintreraction = 0.02). Conclusions In this observational analysis of non-randomized BB treatment, there was no suggestion that BB use was associated with worse HF outcomes in HFmrEF/HFpEF, even after extensive adjustment for other prognostic variables.
An examination of the vacation behaviors of United States emergency physicians
Courtney, D. Mark , Sinsky, Christine A. , Trockel, Mickey , Carlasare, Lindsey E. , Shanafelt, Tait D. , Lu, Dave W , Courtney, D Mark , Shanafelt, Tait D , Wang, Hanhan , Dyrbye, Liselotte N. , West, Colin P.

Academic Emergency Medicine | August 31, 2024 | Volume: 32 | Issue: 1 | Pages: 87-90

10.1111/acem.15005 | PMID 39215456 Get It

Bridging the gap: Multi‐omics profiling of brain tissue in Alzheimer's disease and older controls in multi‐ethnic populations
Reddy, Joseph S. , Heath, Laura , Linden, Abby Vander , Allen, Mariet , Lopes, Kátia de Paiva , Wang, Erming , Poehlman, William L. , Quicksall, Zachary , Runnels, Alexi , Duong, Duc M. , Yin, Luming, Xu, Kaiming , Modeste, Erica , Dammer, Eric B. , Ping, Lingyan , Oatman, Stephanie R., Scanlan, Jo, Ho, Charlotte C.G. , Carrasquillo, Minerva M. , Atık, Merve, Yepez, Geovanna, Mitchell, Adriana O., Nguyen, Thuy , Chen, Xianfeng , Reddy, Hasini, Xiao, Harrison, Seshadri, Sudha , Mayeux, Richard , Beach, Thomas G. , Haroutunian, V., Fox, Edward J., Gearing, Marla , Wingo, Aliza P. , Wingo, Thomas S. , Jager, Philip L. De , Zhang, Bin , Bennett, David A. , Seyfried, Nicholas T. , Greenwood, Anna K. , Ertekin‐Taner, Nilüfer , Bennett, David A. , Ho, Charlotte, Greenwood, Anna K , Seshadri, Sudha , Dammer, Eric B , Wingo, Thomas S , Seifar, Fatemeh , Ma, Yiyi , Wang, Yanling , Shantaraman, Anantharaman , Carrasquillo, Minerva M. , Márquez, David X. , Prokop, Stefan , Lee, Edward B. , Serrano, Geidy E. , Teich, Andrew F. , Lah, James J. , Levey, Allan I. , Dickson, Dennis W. , Barnes, Lisa L.

Alzheimer's & Dementia | August 31, 2024 | Volume: 20 | Issue: 10 | Pages: 7174-7192

10.1002/alz.14208 | PMID 39215503 Get It

Abstract INTRODUCTION Multi‐omics studies in Alzheimer's disease (AD) revealed many potential disease pathways and therapeutic targets. Despite their promise of precision medicine, these studies lacked Black Americans (BA) and Latin Americans (LA), who are disproportionately affected by AD. METHODS To bridge this gap, Accelerating Medicines Partnership in Alzheimer's Disease (AMP‐AD) expanded brain multi‐omics profiling to multi‐ethnic donors. RESULTS We generated multi‐omics data and curated and harmonized phenotypic data from BA ( n = 306), LA ( n = 326), or BA and LA ( n = 4) brain donors plus non‐Hispanic White ( n = 252) and other ( n = 20) ethnic groups, to establish a foundational dataset enriched for BA and LA participants. This study describes the data available to the research community, including transcriptome from three brain regions, whole genome sequence, and proteome measures. DISCUSSION The inclusion of traditionally underrepresented groups in multi‐omics studies is essential to discovering the full spectrum of precision medicine targets that will be pertinent to all populations affected with AD. Highlights Accelerating Medicines Partnership in Alzheimer's Disease Diversity Initiative led brain tissue profiling in multi‐ethnic populations. Brain multi‐omics data is generated from Black American, Latin American, and non‐Hispanic White donors. RNA, whole genome sequencing and tandem mass tag proteomicsis completed and shared. Multiple brain regions including caudate, temporal and dorsolateral prefrontal cortex were profiled.
Predictors of patient satisfaction after surgery for grade 1 degenerative spondylolisthesis: a 5-year analysis of the Quality Outcomes Database
Dru, Alexander, Johnson, Sarah E. , Linzey, Joseph R. , Foley, Kevin T. , DiGiorgio, Anthony M. , Alan, Nima , Coric, Domagoj , Potts, Eric A. , Bisson, Erica F. , Knightly, John J. , Fu, Kai-Ming, Shaffrey, Mark E., Weaver, Jason, Bydon, Mohamad , Chou, Dean , Meyer, Scott A., Asher, Anthony L. , Shaffrey, Christopher I. , Slotkin, Jonathan R., Wang, Michael Y. , Haid, Regis W., Glassman, Steven D. , Virk, Michael S. , Mummaneni, Praveen V. , Park, Paul

Journal of Neurosurgery: Spine | August 31, 2024 | Volume: 41 | Issue: 5 | Pages: 658-665

10.3171/2024.5.spine24227 | PMID 39213671 Get It

OBJECTIVE Lumbar decompression and/or fusion surgery is a common operation for symptomatic lumbar spondylolisthesis refractory to conservative management. Multiyear follow-up of patient outcomes can be difficult to obtain but allows for identification of preoperative patient characteristics associated with durable pain relief, improved functional outcome, and higher patient satisfaction. METHODS A query of the Quality Outcomes Database (QOD) low-grade spondylolisthesis module for patients who underwent surgery for grade 1 lumbar spondylolisthesis (from July 2014 to June 2016 at the 12 highest-enrolling sites) was used to identify patient satisfaction, as measured with the North American Spine Society (NASS) questionnaire, which uses a scale of 1–4. Patients were considered satisfied if they had a score ≤ 2. Multivariable logistic regression was performed to identify baseline demographic and clinical predictors of long-term satisfaction 5 years after surgery. RESULTS Of 573 eligible patients from a cohort of 608, patient satisfaction data were available for 81.2%. Satisfaction (NASS score of 1 or 2) was reported by 389 patients (83.7%) at 5-year follow-up. Satisfied patients were predominantly White and ambulation independent and had lower baseline BMI, lower back pain levels, lower Oswestry Disability Index (ODI) scores, and greater EQ-5D index scores at baseline when compared to the unsatisfied group. No significant differences in reoperation rates between groups were reported at 5 years. On multivariate analysis, patients who were independently ambulating at baseline had greater odds of long-term satisfaction (OR 1.12, p = 0.04). Patients who had higher 5-year ODI scores (OR 0.99, p < 0.01) and were uninsured (OR 0.43, p = 0.01) were less likely to report long-term satisfaction. CONCLUSIONS Lumbar surgery for the treatment of grade 1 spondylolisthesis can provide lasting pain relief with high patient satisfaction. Baseline independent ambulation is associated with a higher long-term satisfaction rate after surgery. Higher ODI scores at 5-year follow-up and uninsured status are associated with lower postoperative long-term satisfaction.
Expert panel curation of 31 genes in relation to limb girdle muscular dystrophy
McNulty, Shannon , Thaxton, Courtney , Elnagheeb, Marwa , Owens, Emma, Flowers, May , Nunnery, Teagan, Self, Autumn, Palus, Brooke, Gorokhova, Svetlana , Kennedy, April , Niu, Zhiyv , Johari, Mridul , Maīga, Alassane Baneye , Macalalad, Kelly, Clause, Amanda , Beckmann, J. , Bronicki, Lucas, Ganesh, Vijay S , Kang, Peter B. , Kesari, Akanchha, Lek, Monkol , Lévy, Jennifer, Rufibach, Laura , Savarese, Marco , Spencer, Melissa J. , Tasca, Giorgio , Weihl, Conrad C. , Gorokhova, Svetlana , Niu, Zhiyv , Clause, Amanda R , Kang, Peter B , Savarese, Marco , Tasca, Giorgio , Thaxton, Courtney , Mohan, Shruthi , Cooper, Sandra T. , Straub, Volker

Annals of Clinical and Translational Neurology | August 31, 2024 | Volume: 11 | Issue: 9 | Pages: 2268-2276

10.1002/acn3.52127 | PMID 39215466 Get It

Abstract Objective Limb girdle muscular dystrophies (LGMDs) are a group of genetically heterogeneous autosomal conditions with some degree of phenotypic homogeneity. LGMD is defined as having onset >2 years of age with progressive proximal weakness, elevated serum creatine kinase levels and dystrophic features on muscle biopsy. Advances in massively parallel sequencing have led to a surge in genes linked to LGMD. Methods The ClinGen Muscular Dystrophies and Myopathies gene curation expert panel (MDM GCEP, formerly Limb Girdle Muscular Dystrophy GCEP) convened to evaluate the strength of evidence supporting gene–disease relationships (GDR) using the ClinGen gene–disease clinical validity framework to evaluate 31 genes implicated in LGMD. Results The GDR was exclusively LGMD for 17 genes, whereas an additional 14 genes were related to a broader phenotype encompassing congenital weakness. Four genes ( CAPN3 , COL6A1 , COL6A2 , and COL6A3 ) were split into two separate disease entities, based on each displaying both dominant and recessive inheritance patterns, resulting in curation of 35 GDRs. Of these, 30 (86%) were classified as definitive, 4 (11%) as moderate, and 1 (3%) as limited. Two genes, POMGNT1 and DAG1 , though definitively related to myopathy, currently have insufficient evidence to support a relationship specifically with LGMD. Interpretation The expert‐reviewed assertions on the clinical validity of genes implicated in LGMDs form an invaluable resource for clinicians and molecular geneticists. We encourage the global neuromuscular community to publish case‐level data that help clarify disputed or novel LGMD associations.
Stereotactic radiosurgery for intracranial dural arteriovenous fistulas: patient outcomes and lessons learned over a 3-decade single-center experience
Peters, Pierce A., Naylor, Ryan M. , Lanzino, Giuseppe, Link, Michael J., Pollock, Bruce E. , Lanzino, Giuseppe

Journal of Neurosurgery | August 31, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-8

10.3171/2024.6.jns24547 | PMID 39213678 Get It

OBJECTIVE The role of stereotactic radiosurgery (SRS) in the management of intracranial dural arteriovenous fistula (dAVF) is unclear given the rarity of this lesion and the variability in treatment paradigms. This study describes a 3-decade experience with the SRS technique and its outcomes for patients with dAVF. METHODS The authors conducted a retrospective analysis of patients with dAVF who had undergone single-fraction SRS in the period from 1990 to 2021. The imaging modality initially used for targeting was angiography alone, then angiography plus MRI, and most recently MRI alone. RESULTS Two hundred twenty-two patients underwent SRS alone (n = 56, 25%) or SRS plus embolization (n = 166, 75%), depending on the severity of symptoms or the presence of cortical venous drainage (CVD). Most patients were women (64%), and the median patient age was 60 years. Common presenting symptoms were pulsatile bruit (55%), visual change or chemosis (21%), headache (10%), and intracerebral hemorrhage (5%). The most frequent dAVF location was the transverse or sigmoid sinus (44%), followed by the cavernous sinus (24%), jugular bulb (9%), and torcula (5%). CVD was noted in 28% of cases, and venous ectasia in 5%. Borden dAVF types among the patients were I (72%), II (20%), and III (8%). Cognard dAVF types among the patients were I (44%), IIa (27%), IIb (5%), IIa+b (15%), III (4%), and IV (5%). The median SRS treatment volume was 7.6 cm3; the median margin and maximum doses were 18 and 36 Gy, respectively. Follow-up after SRS was available for 209 patients (median follow-up 31 months). Obliteration was noted in 75% of the patients (110/147) with follow-up vascular imaging; the median time to obliteration was 37 months. Multivariate analysis revealed that a cavernous sinus dAVF location was predictive of radiological obliteration (HR 1.86, 95% CI 1.08–3.18, p = 0.024). The absence of CVD was predictive of obliteration in subgroup analysis of non–cavernous sinus dAVF (HR 0.53, 95% CI 0.29–0.98, p = 0.04). Symptoms resolved in 86% of patients (160/185) with clinical follow-up. Twelve patients (5.4%) had complications related to angiography for SRS planning (n = 2, 0.9%), embolization (n = 3, 1.4%), post-SRS hemorrhage (n = 1, 0.5%), delayed sinus thrombosis (n = 1, 0.5%), radiation-induced tumors (n = 2, 0.9%), and chronic encapsulated expanding hematoma (n = 3, 1.4%). CONCLUSIONS SRS alone or in conjunction with embolization provided obliteration and symptom relief for the majority of patients with dAVF, with a low rate of procedure-related morbidity. Patients are at risk for late radiation-related complications, which can require treatment many years after SRS.